CAPS nod from CHMP for Sobi's Kineret
This article was originally published in Scrip
Executive Summary
The EU's Committee for Medicinal Products for Human Use (CHMP) has recommended the use of Swedish Orphan Biovitrum's rheumatoid arthritis drug Kineret (anakinra) for the treatment of patients with cryopyrin-associated periodic syndromes (CAPS).